Sydney, June 10, 2026, 01:02 AEST
- Sonic Healthcare finished up 2.1% at A$19.75 on Tuesday, bucking the trend on a softer S&P/ASX 200.
- Investors were eyeing new warnings on cost pressure for the pathology sector as the market looked toward FY27.
- Healius has already pointed to wage and funding pressure, keeping margin risks on the sector’s radar.
Sonic Healthcare Limited moved higher Tuesday while the broader Australian market slipped. Investors shrugged off new concerns about FY27 costs and stuck with the diagnostics group after it kept its earnings outlook steady.
Sonic finished the session 41 cents higher at A$19.75, up 2.1%. Shares traded in a range from A$19.30 to A$19.75, with volume near 2.7 million, according to its investor-centre quote. The last price was recorded at 4:00 p.m. on June 9, which lines up with the close of regular ASX cash trading at 16:00 Sydney time.
S&P/ASX 200 ended down 0.24% at 8,604.20 Tuesday after materials dragged on the index. Healthcare names held up better, which helped limit losses for the broader market.
Sonic could be looking at FY27 cost risk, according to a report out Monday. The report flagged the same pathology-sector issues hitting Healius — weak Medicare funding, higher transport costs and wage outcomes from the Fair Work Commission — as a risk for Sonic.
Sonic hasn’t shown the trading pattern of a stock close to a downgrade. For now, the market seems to think Sonic can make it through FY26 without lowering guidance, with offshore earnings and market share in Australia giving some support.
Sonic’s February figures back that up. The company posted first-half revenue of A$5.45 billion, up 17%. EBITDA came in at A$907 million, up 10%. Net profit hit A$262 million, gaining 11%. EBITDA — earnings before interest, tax, depreciation and amortisation — strips out some financing and accounting costs to show operating profit.
Sonic kept its FY26 EBITDA guidance at A$1.87 billion to A$1.95 billion on a constant-currency basis, which excludes currency moves. CEO Jim Newcombe said the first-half result pointed to the “strength and global diversity” of Sonic’s business. Sonic Healthcare Investor Centre
Healius stands apart because of that diversity. The company guided to FY26 underlying EBITDA of A$259 million to A$264 million and underlying EBIT of A$30 million to A$35 million back in May. It also warned that pathology labour costs were set to rise due to Fair Work Commission findings on gender-based undervaluation.
Healius said the federal budget offered no extra money for pathology, and most tests remain under the indexation freeze. The company also warned the sector gets no help to cover rising wages. Investors have already been zeroing in on this pathology issue.
Sonic’s new update delivered a mixed view. Organic growth was 5% in its Australian labs. Germany saw benefit from the LADR deal, while Switzerland and the UK posted integration gains. But in the U.S., Sonic reported weak organic growth and restructuring costs weighed on margins.
But the trade isn’t one-way. If open wage rulings, enterprise bargaining, or higher transport costs bite harder in FY27 than the market has priced in, Sonic’s size may not protect its margins. The company has warned that decisions from government, billing rules and surprise cost increases can push results away from forecasts.
Sonic got a pass from buyers at Tuesday’s close. The question now is if management can hold onto that FY26 guidance and offer a clearer view on costs for next year.
